Stockreport

Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH

Ionis Pharmaceuticals, Inc.  (IONS) 
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ionispharma.com